Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis



Status:Completed
Conditions:Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - Any
Updated:5/16/2018
Start Date:July 2015
End Date:December 31, 2017

Use our guide to learn which trials are right for you!

Steady-State Pharmacokinetics of Tedizolid in Plasma and Sputum of Patients With Cystic Fibrosis

The proposed study is designed to characterize the pharmacokinetics of intravenous and oral
tedizolid in patients with Cystic Fibrosis.

Recent epidemiological studies have demonstrated that the presence of methicillin-resistant
Staphylococcus aureus (MRSA) in the airways of patients with CF is associated with more rapid
lung function decline and a higher mortality. Tedizolid is a new antibiotic with potent
activity against MRSA. Tedizolid is currently FDA approved for treatment of skin soft tissue
infections with MRSA. The proposed study is designed to characterize the pharmacokinetics of
intravenous and oral tedizolid in patients with CF.

Inclusion Criteria:

- Diagnosis of CF based on positive sweat chloride or known CF mutation

- Age > 17 years

- Able to spontaneously expectorate sputum

Exclusion Criteria:

- Any clinically significant laboratory abnormalities

- Presence of an ongoing acute pulmonary exacerbation

- Pregnancy

- Serious past allergy to linezolid or tedizolid

- No alcohol, nicotine, or caffeine-containing products during the study period
We found this trial at
1
site
Los Angeles, California 90033
213) 740-2311
University of Southern California The University of Southern California is one of the world’s leading...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials